Post hoc analysis of the aborted LTE period
SAEs
The LTE period of the study was terminated early owing to the lack of efficacy demonstrated upon readout after the placebo-controlled period. Data from the LTE period were analyzed up to week 104, during which the sample size was still substantial (the Long-term exposure to gosuranemab was well tolerated by the participants. The safety profiles during the LTE period were similar to those during the placebo-controlled period, and no additional safety concerns were observed with the limited exposure to gosuranemab in the LTE period. The overall incidence of AEs and SAEs in the LTE period was similar between the early-start (